Wednesday, February 19, 2020 Daily Archives

scientist handling equipment

Introducing New Digital Tools to Enhance Raw Material Verification

by

This webcast features: Antonia Guerra, Global Digital and Data Science Leader, Field & Safety Instruments, Thermo Fisher Scientific™ This webinar presents the new virtual companion to the Thermo Scientific™ TruScan™ RM Handheld Raman Analyzer, the Virtual TruScan™ RM (VTR) App, which creates efficiencies in material identity verification. This first-of-its-kind digital tool puts the TruScan RM’s decision algorithm in the cloud and allows for method validation and spectral re-processing without the need for a physical sample. With the VTR app, wait…

February 19, 2020

KKR pumps €50m into Univercells through Gamma funding platform

by

Over a quarter of Gamma Bioscience’s $200 million funding for next-generation bioprocessing technologies will be used to support Univercells’ biomanufacturing tech platforms. In January, global investment firm KKR launched Gamma Bioscience, a portfolio of life sciences tools subsidiaries. The first company to fall under the umbrella was Astrea Bioseparations, a ligand discovery and adsorbent development services firm, previously known as Prometic Bioseparations, acquired by KKR for around $100 million (€93 million) in November 2019. Now KKR and co-investors have committed…

February 19, 2020

Audentes $109m NC expansion boon for Astellas gene therapy plans

by

Astellas acquisition Audentes has laid plans to build a 135,000 square-foot gene therapy manufacturing plant in Sanford, North Carolina. The $109 million (€100 million) plant is expected to be operational in 2021 and will support Audentes’ gene therapy portfolio. The firm’s lead product is AT132, a Phase I/II clinical-stage experimental treatment for X-linked myotubular myopathy (XLMTM), though the firm is also developing gene therapies for Pompe disease and Duchenne Muscular Dystrophy (DMD). “Our investment in large-scale manufacturing has always been…

February 19, 2020

Teva highlights fasinumab and Celltrion biosims deal as drivers

by

Teva says the monoclonal antibody (mAb) candidate fasinumab has “big potential†and expects to see Phase III data this year. The Israel headquartered generics firm spoke about fasinumab – the osteoarthritis pain drug – during its fourth quarter earnings call last week. CEO Kare Schultz told analysts “In novel biologics, we have a lot of different things going on. “The most exciting short-term is fasinumab that we are developing together with Regeneron and where we hope to see data this year…

February 19, 2020